Published in AIDS Weekly, November 5th, 2001
Based on developments in genomics technology, novel therapeutics, and the increasing need for effective vaccines, TherImmune has made significant investments in establishing unique capabilities in the vaccine development arena. The company is excited to be working with NIAID in this important and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.